WHETHER С-MYC IS A PROGNOSTIC FACTOR IN PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA?
Keywords:
primary mediastinal large B-cell lymphoma, с-myc expression, translocation t(8;14), FISH.Abstract
Summary. The adverse impact of c-MYC for diffuse
large B-cell lymphoma is confirmed by numerous studies.
However, primary mediastinal lymphoma sub-options
such data. Aim: to investigate the prognostic significance
of c-MYC expression and translocations t (8;14) inpatients
with primary mediastinal large B-cell lymphoma. Materials and methods: immunohistochemical study to determine c-myc expression and FISH-analisys and to identify translocation t(8;14) were done on 33 tissue specimens.
Results: in 51.6% of cases was strong and moderate nuclear expression of c-myc. Among these patients in one third
of cases was revealed translocation t(8;14) byFISH-study.
were identified some differences of marker’s expression in
women and men. Conclusion: there were no differences in
the course of disease in patients with a different c-MYC expression status, as well as the presence or absence of disturbances of c-MYC structure.
References
Oberley MJ, Rajguru SA, Zhang C, et al. Immunohistochemical evaluation of MYC expression in mantle cell lymphoma. Histopathology 2013; 63: 499–508.
Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533–7.
Wolfera A, Wittnera BS, Daniel Irimia, et al. MYC regulation of a «poor-prognosis» metastatic cancer cell state. PNAS
; 107 (8): 3698–703.
Campanero MR. Mechanisms involved in Burkitt’s lymphoma tumor formation. Clin Transl Oncol 2008; 10: 250.
Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol 2011; 18: 219–28.
Valera A, López-Guillermo A, Cardesa-Salzmann Т. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma
treated with immunochemotherapy. Haematologica 2013; 98 (10): 1554–62.
Aukema SM, Siebert R, Schuuring Ed. Double-hit B-cell lymphomas. Blood 2011; 117: 2319–31.
Tapia G, Lopez R, Munoz-Marmol AM, et al. Immunohistochemical detection of MYC protein correlates with MYC
gene status in aggressive B cell lymphomas. Histopathology 2011; 59: 672–8.
Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17: 123–30.
Rieger M, Osterborg A, Pettengell R, et al. MabThera International Trial (MInT). Group Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011; 22 (3): 664–70.
Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that
of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–9.
Scarpa A, Borgato L, Chilosi M, et al. Evidence of cMYC gene abnormalities in mediastinal large B-cell lymphoma
of young adult age. Blood 1991; 78: 780–8.
Tsang P, Cesarman E, Chadburn A, et al. Molecular characterization of primary mediastinal B-cell lymphoma. Am J Pathol 1996; 148: 2017–25.
Scarpa A, Moore PS, Rigaud G, et al. Molecular features of primary mediastinal B-cell lymphoma: involvement of
p16INK4A, p53 and c-myc. Br J Haematol 1999; 107: 106–13.
Li KD, Miles R, Sheryl R, еt al. Clinicopathologic evaluation of MYC expression in primary mediastinal (Thymic)
large B-cell lymphoma. Am J Clin Pathol 2015; 143: 598–604.
Gaulard P, Harris N, Pileri S, et al. Primary mediastinal (thymic) large B-cell lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2008; 250–3
